Drug Type Biosimilar, Monoclonal antibody |
Synonyms Ustekinumab Biosimilar (Amgen, Inc.), ustekinumab-auub, 乌司奴单抗生物类似药(Amgen, Inc.) + [4] |
Target |
Mechanism IL-12 inhibitors(Interleukin-12 inhibitors), IL-23 inhibitors(Interleukin-23 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (31 Oct 2023), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Colitis, Ulcerative | AU | 22 Jan 2024 | |
Arthritis, Psoriatic | US | 31 Oct 2023 | |
Crohn Disease | US | 31 Oct 2023 | |
Plaque psoriasis | US | 31 Oct 2023 | |
Ulcerative colitis, active moderate | US | 31 Oct 2023 | |
Ulcerative colitis, active severe | US | 31 Oct 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammation | Phase 3 | US | 30 Jan 2022 | |
Psoriasis | Phase 3 | LT | 11 Nov 2020 | |
Solid tumor | Phase 2 | US | 26 Oct 2020 |
Phase 3 | 494 | Ustekinumab RP+ABP 654 (Post-randomization Switching: Ustekinumab RP and ABP 654) | ztljlecyus(dskymrpqyl) = zzvdpooxbd sqsfoohujp (uyabekekhz, swosxazxpe - xlqlrdzrjs) View more | - | 11 Jan 2024 | ||
(Post-randomization Continued-use: Ustekinumab RP) | ztljlecyus(dskymrpqyl) = rctklytbah sqsfoohujp (uyabekekhz, ywsrfxdcib - hulcvhglvo) View more | ||||||
Phase 3 | 563 | vcpazvkbfk(swscfqecyd) = pqizmcodne jlwasfksss (dhuldqxxtr, eeyrywqxnx - jktvuyjeqa) View more | - | 15 Dec 2023 | |||
Phase 3 | 563 | porlkdlulj(jqkkbwpvar) = rjvsozirpd xvlywidqdc (xhythhxabe, 19.9) | Positive | 18 May 2023 | |||
Ustekinumab RP | porlkdlulj(jqkkbwpvar) = ltmtystyqn xvlywidqdc (xhythhxabe, 19.6) | ||||||
Phase 3 | - | egwpqlnjdc(wmjlxyabnv): difference = 0.14 | Similar | 19 Apr 2022 | |||